Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 2
1995 1
1996 1
2000 7
2001 5
2002 6
2003 15
2004 15
2005 26
2006 30
2007 36
2008 50
2009 33
2010 27
2011 25
2012 22
2013 23
2014 11
2015 24
2016 20
2017 19
2018 22
2019 20
2020 19
2021 21
2022 17
2023 12
2024 9
2025 9
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

463 results

Results by year

Filters applied: . Clear all
Page 1
Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus.
Kapur J, Elm J, Chamberlain JM, Barsan W, Cloyd J, Lowenstein D, Shinnar S, Conwit R, Meinzer C, Cock H, Fountain N, Connor JT, Silbergleit R; NETT and PECARN Investigators. Kapur J, et al. N Engl J Med. 2019 Nov 28;381(22):2103-2113. doi: 10.1056/NEJMoa1905795. N Engl J Med. 2019. PMID: 31774955 Free PMC article. Clinical Trial.
RESULTS: A total of 384 patients were enrolled and randomly assigned to receive levetiracetam (145 patients), fosphenytoin (118), or valproate (121). Reenrollment of patients with a second episode of status epilepticus accounted for 16 additional instances of randomization …
RESULTS: A total of 384 patients were enrolled and randomly assigned to receive levetiracetam (145 patients), fosphenytoin (118), or …
Levetiracetam Versus Phenobarbital for Neonatal Seizures: A Randomized Controlled Trial.
Sharpe C, Reiner GE, Davis SL, Nespeca M, Gold JJ, Rasmussen M, Kuperman R, Harbert MJ, Michelson D, Joe P, Wang S, Rismanchi N, Le NM, Mower A, Kim J, Battin MR, Lane B, Honold J, Knodel E, Arnell K, Bridge R, Lee L, Ernstrom K, Raman R, Haas RH; NEOLEV2 INVESTIGATORS. Sharpe C, et al. Pediatrics. 2020 Jun;145(6):e20193182. doi: 10.1542/peds.2019-3182. Epub 2020 May 8. Pediatrics. 2020. PMID: 32385134 Free PMC article. Clinical Trial.
Our objectives were to study the efficacy and safety of levetiracetam compared with phenobarbital as a first-line treatment of neonatal seizures. ...Higher-dose studies of levetiracetam are warranted, and definitive studies with long-term outcome measures are needed …
Our objectives were to study the efficacy and safety of levetiracetam compared with phenobarbital as a first-line treatment of neonat …
The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
Marson A, Burnside G, Appleton R, Smith D, Leach JP, Sills G, Tudur-Smith C, Plumpton C, Hughes DA, Williamson P, Baker GA, Balabanova S, Taylor C, Brown R, Hindley D, Howell S, Maguire M, Mohanraj R, Smith PE; SANAD II collaborators. Marson A, et al. Lancet. 2021 Apr 10;397(10282):1363-1374. doi: 10.1016/S0140-6736(21)00247-6. Lancet. 2021. PMID: 33838757 Free PMC article. Clinical Trial.
SANAD II was designed to assess non-inferiority of both levetiracetam and zonisamide to lamotrigine for the primary outcome of time to 12-month remission. ...Patients were randomly assigned to receive lamotrigine (n=330), levetiracetam (n=332), or zonisamide (n=328) …
SANAD II was designed to assess non-inferiority of both levetiracetam and zonisamide to lamotrigine for the primary outcome of time t …
Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity: A Randomized Clinical Trial.
Vossel K, Ranasinghe KG, Beagle AJ, La A, Ah Pook K, Castro M, Mizuiri D, Honma SM, Venkateswaran N, Koestler M, Zhang W, Mucke L, Howell MJ, Possin KL, Kramer JH, Boxer AL, Miller BL, Nagarajan SS, Kirsch HE. Vossel K, et al. JAMA Neurol. 2021 Nov 1;78(11):1345-1354. doi: 10.1001/jamaneurol.2021.3310. JAMA Neurol. 2021. PMID: 34570177 Free PMC article. Clinical Trial.
INTERVENTIONS: Group A received placebo twice daily for 4 weeks followed by a 4-week washout period, then oral levetiracetam, 125 mg, twice daily for 4 weeks. Group B received treatment using the reverse sequence. ...CONCLUSIONS AND RELEVANCE: In this randomized clinical t …
INTERVENTIONS: Group A received placebo twice daily for 4 weeks followed by a 4-week washout period, then oral levetiracetam, 125 mg, …
Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial.
Chamberlain JM, Kapur J, Shinnar S, Elm J, Holsti M, Babcock L, Rogers A, Barsan W, Cloyd J, Lowenstein D, Bleck TP, Conwit R, Meinzer C, Cock H, Fountain NB, Underwood E, Connor JT, Silbergleit R; Neurological Emergencies Treatment Trials; Pediatric Emergency Care Applied Research Network investigators. Chamberlain JM, et al. Lancet. 2020 Apr 11;395(10231):1217-1224. doi: 10.1016/S0140-6736(20)30611-5. Epub 2020 Mar 20. Lancet. 2020. PMID: 32203691 Free PMC article. Clinical Trial.
In the Established Status Epilepticus Treatment Trial (ESETT) we compared the efficacy and safety of levetiracetam, fosphenytoin, and valproate in established status epilepticus, and here we describe our results after extending enrolment in children to compare outcomes in …
In the Established Status Epilepticus Treatment Trial (ESETT) we compared the efficacy and safety of levetiracetam, fosphenytoin, and …
The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
Marson A, Burnside G, Appleton R, Smith D, Leach JP, Sills G, Tudur-Smith C, Plumpton C, Hughes DA, Williamson P, Baker GA, Balabanova S, Taylor C, Brown R, Hindley D, Howell S, Maguire M, Mohanraj R, Smith PE; SANAD II collaborators. Marson A, et al. Lancet. 2021 Apr 10;397(10282):1375-1386. doi: 10.1016/S0140-6736(21)00246-4. Lancet. 2021. PMID: 33838758 Free PMC article. Clinical Trial.
For participants aged 12 years or older, the initial advised maintenance doses were 500 mg twice per day for levetiracetam and valproate, and for children aged 5-12 years, the initial daily maintenance doses advised were 25 mg/kg for valproate and 40 mg/kg for levetirac …
For participants aged 12 years or older, the initial advised maintenance doses were 500 mg twice per day for levetiracetam and valpro …
Safety and efficacy of prophylactic levetiracetam for prevention of epileptic seizures in the acute phase of intracerebral haemorrhage (PEACH): a randomised, double-blind, placebo-controlled, phase 3 trial.
Peter-Derex L, Philippeau F, Garnier P, André-Obadia N, Boulogne S, Catenoix H, Convers P, Mazzola L, Gouttard M, Esteban M, Fontaine J, Mechtouff L, Ong E, Cho TH, Nighoghossian N, Perreton N, Termoz A, Haesebaert J, Schott AM, Rabilloud M, Pivot C, Dhelens C, Filip A, Berthezène Y, Rheims S, Boutitie F, Derex L. Peter-Derex L, et al. Lancet Neurol. 2022 Sep;21(9):781-791. doi: 10.1016/S1474-4422(22)00235-6. Lancet Neurol. 2022. PMID: 35963261 Clinical Trial.
We aimed to assess whether prophylactic levetiracetam would reduce the risk of acute seizures in patients with intracerebral haemorrhage. ...No treatment-related death was reported in either group. INTERPRETATION: Levetiracetam might be effective in preventing acute …
We aimed to assess whether prophylactic levetiracetam would reduce the risk of acute seizures in patients with intracerebral haemorrh …
Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.
Topp MS, van Meerten T, Houot R, Minnema MC, Bouabdallah K, Lugtenburg PJ, Thieblemont C, Wermke M, Song KW, Avivi I, Kuruvilla J, Dührsen U, Zheng Y, Vardhanabhuti S, Dong J, Bot A, Rossi JM, Plaks V, Sherman M, Kim JJ, Kerber A, Kersten MJ. Topp MS, et al. Br J Haematol. 2021 Nov;195(3):388-398. doi: 10.1111/bjh.17673. Epub 2021 Sep 29. Br J Haematol. 2021. PMID: 34590303 Free PMC article. Clinical Trial.
Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.
Marson AG, Burnside G, Appleton R, Smith D, Leach JP, Sills G, Tudur-Smith C, Plumpton CO, Hughes DA, Williamson PR, Baker G, Balabanova S, Taylor C, Brown R, Hindley D, Howell S, Maguire M, Mohanraj R, Smith PE. Marson AG, et al. Health Technol Assess. 2021 Dec;25(75):1-134. doi: 10.3310/hta25750. Health Technol Assess. 2021. PMID: 34931602 Free article. Clinical Trial.
BACKGROUND: Levetiracetam (Keppra( ), UCB Pharma Ltd, Slough, UK) and zonisamide (Zonegran( ), Eisai Co. ...INTERVENTIONS: Participants with focal epilepsy were randomised to receive lamotrigine, levetiracetam or zonisamide. Participants with generalised or unclassi …
BACKGROUND: Levetiracetam (Keppra( ), UCB Pharma Ltd, Slough, UK) and zonisamide (Zonegran( ), Eisai Co. ...INTERVENTIONS: Participan …
Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis.
Szaflarski JP, Sangha KS, Lindsell CJ, Shutter LA. Szaflarski JP, et al. Neurocrit Care. 2010 Apr;12(2):165-72. doi: 10.1007/s12028-009-9304-y. Neurocrit Care. 2010. PMID: 19898966 Clinical Trial.
We performed a study comparing intravenous (IV) levetiracetam (LEV) to IV phenytoin (PHT) for seizure prophylaxis after neurological injury. ...
We performed a study comparing intravenous (IV) levetiracetam (LEV) to IV phenytoin (PHT) for seizure prophylaxis after neurological …
463 results